Yale researchers have introduced countless medical and health advances over the last century, including the first success with antibiotics in the United States and the first use of chemotherapy to treat cancer. University scientists have been responsible for the identification of Lyme disease and the discovery of genes responsible for high blood pressure, osteoporosis, dyslexia, and Tourette's syndrome, among other disorders. Early work on the artificial heart and the creation of the first insulin pump took place at Yale, as did seminal discoveries about how the cell and its components function at the molecular level. Today, research activities take place in a wide range of departments, programs, and centers.
As of fiscal year 2013 Yale research has had 1,815 awards totaling $510.4 million, 416 U.S. and 704 worldwide active patents for Yale inventions, and 58 Yale-founded biotech companies.
The School of Medicine has extraordinary strength in the basic sciences and consistently ranks in the top handful of medical schools receiving funding from the National Institutes of Health.
Productive and prominent programs in both basic and clinical research are fundamental to the development of clinical excellence and our academic mission.
Our Vascular Biology Laboratory, under the direction of Dr. Sumpio, has both national and international visibility and is well-funded through NIH, AHA, and VA sources. This vigorous research program, focusing on delineating molecular events in the arterial wall in response to mechanical forces, has involvement by students, residents, visiting fellows, as well as faculty.
Dr. Dardik’s research program focuses on factors that contribute to the endothelial cell and whole blood vessel differentiated phenotype. He is currently examining the role of shear stress in endothelial cell signal transduction and extracellular protein secretion.
Dr. Gusberg’s clinical research program is focused on predicting and assessing outcomes of neuropsychological impact of carotid endarterectomy; predicting blood pressure and functional response to renal revascularization by stent or bypass; evaluating functional and quality of life outcomes in patients undergoing elective thoracoabdominal and infrarenal aortic aneurysm repair (open or endovascular).
Dr. Bart Muhs has special expertise in endovascular techniques, especially related to thoracic and abdominal aortic procedures. He had formal training in endovascular procedures during his vascular surgery training as well as an additional year of post-fellowship experience. He was a Marco Polo Fellow and spent six months in Utrecht, Netherlands, training on fenestrated aortic grafts. Dr. Muhs is actively engaged in evaluating endovascular treatments via clinical research and acting as the principle investigator on Yale endovascular clinical trials.
Bauer Sumpio, M.D., Ph.D.
Chief, Vascular Surgery
Yale University School of Medicine
333 Cedar Street, FMB 137
PO Box 208062
New Haven, Connecticut 06520-8062